Please complete Pre-test

Chapter 1 of 1



Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Prognostication in AML has become more challenging as each new treatment regimen receives approval. In this activity, Dr. Amir Fathi discusses the current standard of care for risk stratification in AML and how to incorporate genetic testing results in treatment selection. The goal of this activity is to improve the knowledge and competency of oncology providers in the safety and efficacy of IDH Inhibitors and their role in the treatment of AML.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify mutational testing strategies that should be used to identify AML patients with IDH1 and IDH2 mutations
  • Outline approaches for management and monitoring of AML patients related to expected time to therapeutic response seen with IDH1/2 inhibitors
  • Describe symptoms of differentiation syndrome associated with IDH1/2 inhibitors, timing of symptom onset and proactive management strategies that will minimize the impact of this treatment-related adverse event
  • Identify other treatment-related adverse events associated with the use of IDH1/2 inhibitors in AML and correlate each with the appropriate and effective management strategies


Practical Strategies for Optimizing IDH Inhibitor-based Therapy in Relapsed/Refractory AML – Amir T. Fathi, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 19, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Amir Fathi graduated summa cum laude from Yale University with a BS degree in molecular, cellular, and developmental biology. He went on to receive his medical degree with honors at the Yale School of Medicine. He also has a master’s degree in epidemiology from Harvard School of Public Health. Dr. Fathi completed his residency training in internal medicine at Massachusetts General Hospital (MGH), and fellowships in both hematology and medical oncology at Johns Hopkins Hospital. He is the Program Director of the Center for Leukemia at the Massachusetts General Hospital Cancer Center; he is also an Associate Professor in Medicine at Harvard Medical School.

Dr. Fathi has presented at national meetings of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), spoken at national academic and educational meetings, and has served on national committees that establish guidelines for the management of acute and chronic leukemias. As faculty at the MGH Cancer Center and Harvard Medical School, Dr. Fathi provides clinical care, supervises trainees, administers a busy clinic, and as the director of clinical research in leukemia, is the lead investigator on numerous clinical trials investigating novel treatments in acute leukemias. His other interests focus on developing translational projects to discover new targets for therapy.

Outcomes for patients with acute myeloid leukemia (AML) continue to be poor despite incremental advances in treatment and supportive care over the last 30 years. Although most patients respond to initial treatment, the majority eventually relapse and many succumb to their disease. Therefore, new and innovative approaches are desperately needed to significantly improve outcomes. As a clinician-scientist with a deep interest in developing novel therapies for AML, Dr. Fathi endeavors to provide outstanding clinical care, teaching, and mentoring, while also conducting translational projects, retrospective research, and clinical trials, with the overarching goal improving the health and outcomes of patients with bone marrow malignancies.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-010-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Amir Fathi has received honoraria related to formal advisory activities from Amphivena Therapeutics, Inc., Pfizer Inc., and Trovagene, Inc., as well as consultant fees from AbbVie Inc., Agios, Celgene Corporation, Daiichi Sankyo, Inc., Forty Seven Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Agios and Celgene.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.